Samsung C&T Corp (028260)
Korea Stock Exchange · Korea · prices in KRW · close of 22 Oct 2026
Key indicators
| Last close | KRW 288,500.00 |
|---|---|
| 52-week range | 200,500.00 – 565,000.00 |
| Return, 1 month / 3 months | −21.4% / −18.5% |
| Return, 1 year / 3 years | +40.3% / +182.8% |
| Trend | Below its 200-day average |
| RSI (14) | 36 |
| Volatility (1 year) | 74.8% |
| Worst drawdown (1 year) | -50.0% |
| Average daily value traded | 133,788.56M KRW |
| Dividend yield | 1.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Samsung C&T Corp is a Korean company with several businesses. Its engineering and construction arm designs and builds tall buildings, industrial plants and infrastructure for clients around the world. A trading and investment division handles commodities, materials and industrial goods. The company also runs fashion labels and leisure operations, including a theme resort. It is based in Seoul, Korea, and serves customers in construction, retail and other industries.
Samsung C&T Corp trades under the code 028260 on the Korea Stock Exchange in Korea, with its price quoted in South Korean won (KRW). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Samsung C&T Corp (028260) trades on the Korea Stock Exchange in Korea. It last closed at KRW 288,500.00 on 22 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 405 of 934 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 40.3% and over the last three months it fell 18.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Korea Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 52 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -16.2% | ||
| From 52-week high | -46.1% | ||
| Momentum | 62 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -18.5% | ||
| 6-month return | -4.2% | ||
| 12-month return, skipping the last month | 78.5% | ||
| Stability (higher is calmer) | 29 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 74.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -50.0% | ||
| Liquidity | 98 · Strong | Trades actively. | |
| Average daily value traded | 133,788.56M KRW | ||
| Zero-volume days | 0.0% | ||
| Income | 33 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.0% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +7.9% |
|---|---|
| 1 month | −21.4% |
| 3 months | −18.5% |
| 6 months | −4.2% |
| 1 year | +40.3% |
| 3 years | +182.8% |
| 5 years | +167.2% |
Signals
| 50-day / 200-day average | 348,340.00 / 344,112.03 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 18,463.39 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 29 Dec 2025 | KRW 2,800.0000 |
| 27 Dec 2024 | KRW 2,600.0000 |
| 27 Dec 2023 | KRW 2,550.0000 |
| 28 Dec 2022 | KRW 2,300.0000 |
| 29 Dec 2021 | KRW 4,200.0000 |
| 29 Dec 2020 | KRW 2,300.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Korea Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.